
## Steven M Kawut

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1387290/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Right Heart Adaptation to Pulmonary ArterialÂHypertension. Journal of the American College of Cardiology, 2013, 62, D22-D33.	1.2	770
2	Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 527-534.	2.5	529
3	A global view of pulmonary hypertension. Lancet Respiratory Medicine,the, 2016, 4, 306-322.	5.2	523
4	Percent Emphysema, Airflow Obstruction, and Impaired Left Ventricular Filling. New England Journal of Medicine, 2010, 362, 217-227.	13.9	473
5	Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan. Annals of Internal Medicine, 2013, 158, 641.	2.0	437
6	Hemodynamics and Survival in Patients With Pulmonary Arterial Hypertension Related to Systemic Sclerosis*. Chest, 2003, 123, 344-350.	0.4	403
7	Sex and Race Differences in Right Ventricular Structure and Function. Circulation, 2011, 123, 2542-2551.	1.6	288
8	Impact of Hepatopulmonary Syndrome on Quality of Life and Survival in Liver Transplant Candidates. Gastroenterology, 2008, 135, 1168-1175.	0.6	236
9	New predictors of outcome in idiopathic pulmonary arterial hypertension. American Journal of Cardiology, 2005, 95, 199-203.	0.7	227
10	Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. Chest, 2007, 132, 998-1006.	0.4	223
11	Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e15-e43.	2.5	220
12	Therapy for Pulmonary Arterial Hypertension in Adults. Chest, 2019, 155, 565-586.	0.4	216
13	Performance of American Thoracic Society-Recommended Spirometry Reference Values in a Multiethnic Sample of Adults. Chest, 2010, 137, 138-145.	0.4	214
14	Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials. Circulation, 2012, 126, 349-356.	1.6	211
15	Genetic Risk Factors for Portopulmonary Hypertension in Patients with Advanced Liver Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 835-842.	2.5	206
16	The Right Ventricle Explains Sex Differences in Survival in Idiopathic Pulmonary Arterial Hypertension. Chest, 2014, 145, 1230-1236.	0.4	166
17	Mammalian Target of Rapamycin Complex 2 (mTORC2) Coordinates Pulmonary Artery Smooth Muscle Cell Metabolism, Proliferation, and Survival in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 864-874.	1.6	162
18	Sex Hormones Are Associated with Right Ventricular Structure and Function. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 659-667.	2.5	156

Steven M Kawut

#	Article	IF	CITATIONS
19	Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transplantation, 2005, 11, 1107-1111.	1.3	154
20	Right Ventricular Structure Is Associated With the Risk of Heart Failure and Cardiovascular Death. Circulation, 2012, 126, 1681-1688.	1.6	145
21	Race and Sex Differences in Response to Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension. Chest, 2012, 141, 20-26.	0.4	129
22	Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. European Respiratory Journal, 2015, 46, 1370-1377.	3.1	129
23	Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension. Circulation, 2011, 123, 2985-2993.	1.6	127
24	Pulmonary Microvascular Blood Flow in Mild Chronic Obstructive Pulmonary Disease and Emphysema. The MESA COPD Study. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 570-580.	2.5	127
25	Outcomes after Lung Retransplantation in the Modern Era. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 114-120.	2.5	116
26	Determinants of Right Ventricular Ejection Fraction in Pulmonary Arterial Hypertension. Chest, 2009, 135, 752-759.	0.4	116
27	Obesity and Right Ventricular Structure and Function. Chest, 2012, 141, 388-395.	0.4	116
28	Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, part II: Epidemiology, risk factors, and outcomes—A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 1104-1113.	0.3	114
29	High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study. European Respiratory Journal, 2016, 48, 1442-1452.	3.1	110
30	Impact of Pulmonary Artery Pressure on Exercise Function in Severe COPD. Chest, 2009, 136, 412-419.	0.4	107
31	Impact of the Hepatopulmonary Syndrome MELD Exception Policy on Outcomes of Patients After Liver Transplantation: An Analysis of the UNOS Database. Gastroenterology, 2014, 146, 1256-1265.e1.	0.6	105
32	Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1168-1175.	2.5	104
33	Echocardiographic and Hemodynamic Predictors of Mortality in Idiopathic Pulmonary Fibrosis. Chest, 2013, 144, 564-570.	0.4	99
34	Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI). Pulmonary Circulation, 2019, 9, 1-32.	0.8	96
35	Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respiratory Medicine, 2005, 99, 1431-1439.	1.3	90
36	Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension. Chest, 2013, 143, 315-323.	0.4	90

Steven M Kawut

#	Article	IF	CITATIONS
37	Tracheobronchomalacia Is Associated with Increased Morbidity in Bronchopulmonary Dysplasia. Annals of the American Thoracic Society, 2017, 14, 1428-1435.	1.5	90
38	Sex and haemodynamics in pulmonary arterial hypertension. European Respiratory Journal, 2014, 43, 523-530.	3.1	89
39	Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 360-368.	2.5	88
40	The Impact of Pulmonary Hypertension in Preterm Infants with Severe Bronchopulmonary Dysplasia through 1 Year. Journal of Pediatrics, 2018, 203, 218-224.e3.	0.9	87
41	Elevated Pulmonary Artery Pressure Is a Risk Factor for Primary Graft Dysfunction Following Lung Transplantation for Idiopathic Pulmonary Fibrosis. Chest, 2011, 139, 782-787.	0.4	85
42	Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 788-800.	2.5	81
43	Cor Pulmonale Parvus in Chronic Obstructive Pulmonary Disease and Emphysema. Journal of the American College of Cardiology, 2014, 64, 2000-2009.	1.2	76
44	von Willebrand Factor Independently Predicts Long-term Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2005, 128, 2355-2362.	0.4	75
45	Percent Emphysema and Right Ventricular Structure and Function. Chest, 2013, 144, 136-144.	0.4	75
46	An Official American Thoracic Society Statement: Pulmonary Hypertension Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 345-355.	2.5	70
47	Physical Activity and Right Ventricular Structure and Function. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 396-404.	2.5	69
48	Tricuspid Annular Plane Systolic Excursion in the Assessment of Right Ventricular Function in Children and Adolescents after Repair of Tetralogy of Fallot. Journal of the American Society of Echocardiography, 2013, 26, 1322-1329.	1.2	68
49	New and Emerging Therapies for Pulmonary Arterial Hypertension. Annual Review of Medicine, 2019, 70, 45-59.	5.0	68
50	Per cent emphysema is associated with respiratory and lung cancer mortality in the general population: a cohort study. Thorax, 2016, 71, 624-632.	2.7	61
51	Obstructive Sleep Apnea and Subclinical Interstitial Lung Disease in the Multi-Ethnic Study of Atherosclerosis (MESA). Annals of the American Thoracic Society, 2017, 14, 1786-1795.	1.5	60
52	Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulmonary Pharmacology and Therapeutics, 2006, 19, 370-374.	1.1	59
53	Rheumatoid arthritis-associated autoantibodies and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. Thorax, 2016, 71, 1082-1090.	2.7	59
54	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI–Cardiovascular Medical Research and Education Fund Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1661-1670.	2.5	59

#	Article	IF	CITATIONS
55	Diastolic Dysfunction Increases the Risk of Primary Graft Dysfunction after Lung Transplant. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1392-1400.	2.5	58
56	Immunoglobulin G Levels before and after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 917-921.	2.5	57
57	Relation of Cardiovascular Risk Factors to Right Ventricular Structure and Function as Determined by Magnetic Resonance Imaging (Results from the Multi-Ethnic Study of Atherosclerosis). American Journal of Cardiology, 2010, 106, 110-116.	0.7	57
58	Predictors of Catastrophic AdverseÂOutcomes in Children With Pulmonary Hypertension Undergoing Cardiac Catheterization. Journal of the American College of Cardiology, 2015, 66, 1261-1269.	1.2	57
59	Traffic-related Air Pollution and the Right Ventricle. The Multi-ethnic Study of Atherosclerosis. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1093-1100.	2.5	54
60	Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function. European Respiratory Journal, 2016, 47, 553-563.	3.1	54
61	Histamine H 2 Receptor Antagonists, LeftÂVentricular Morphology, and HeartÂFailureÂRisk. Journal of the American College of Cardiology, 2016, 67, 1544-1552.	1.2	54
62	Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1800467.	3.1	54
63	Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2016, 13, 25-30.	1.5	53
64	Outcomes of Extended Donor Lung Recipients after Lung Transplantation. Transplantation, 2005, 79, 310-316.	0.5	52
65	Pulmonary vascular volume, impaired left ventricular filling and dyspnea: The MESA Lung Study. PLoS ONE, 2017, 12, e0176180.	1.1	50
66	2-Year Outcomes After Complete or Staged Procedure for TetralogyÂofÂFallotÂin Neonates. Journal of the American College of Cardiology, 2019, 74, 1570-1579.	1.2	49
67	Serum Albumin Concentration and Waiting List Mortality in Idiopathic Interstitial Pneumonia. Chest, 2009, 135, 929-935.	0.4	48
68	Latent Class Analysis Identifies Distinct Phenotypes of Primary Graft Dysfunction After Lung Transplantation. Chest, 2013, 144, 616-622.	0.4	48
69	Are Hemodynamics Surrogate End Points in Pulmonary Arterial Hypertension?. Circulation, 2014, 130, 768-775.	1.6	46
70	Occupational Exposures and Subclinical Interstitial Lung Disease. The MESA (Multi-Ethnic Study of) Tj ETQq0 0 0 2017, 196, 1031-1039.	rgBT /Ove 2.5	erlock 10 Tf 50 46
71	Quantitative Evidence for Revising the Definition of Primary Graft Dysfunction after Lung Transplant. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 235-243.	2.5	45
72	Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 624-630.	0.3	43

5

#	Article	IF	CITATIONS
73	Investigational new drug enabling angiotensin oral-delivery studies to attenuate pulmonary hypertension. Biomaterials, 2020, 233, 119750.	5.7	42
74	Lung Retransplantation. Clinics in Chest Medicine, 2011, 32, 367-377.	0.8	39
75	Risk Factors and Outcomes of Hypogammaglobulinemia after Lung Transplantation. Transplantation, 2005, 79, 1723-1726.	0.5	38
76	Serotonin Transporter Polymorphisms in Patients With Portopulmonary Hypertension. Chest, 2009, 135, 1470-1475.	0.4	38
77	Racial and ethnic differences in pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 793-796.	0.8	38
78	Validity of the Surface Electrocardiogram Criteria for Right Ventricular Hypertrophy. Journal of the American College of Cardiology, 2014, 63, 672-681.	1.2	36
79	Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement. American Journal of Respiratory and Critical Care Medicine, 2017, 196, e32-e47.	2.5	36
80	Pulse Oximetry Is Insensitive for Detection of Hepatopulmonary Syndrome in Patients Evaluated for Liver Transplantation. Hepatology, 2019, 69, 270-281.	3.6	36
81	Surrogate and Combined End Points in Pulmonary Arterial Hypertension. Proceedings of the American Thoracic Society, 2008, 5, 617-622.	3.5	35
82	Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury. JCI Insight, 2018, 3, .	2.3	35
83	Soluble P-Selectin and the Risk of Primary Graft Dysfunction After Lung Transplantation. Chest, 2009, 136, 237-244.	0.4	34
84	BMP9/10 in Pulmonary Vascular Complications of Liver Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1575-1578.	2.5	32
85	Interleukin-6 and Tumor Necrosis Factor-α Are Associated with Quality of Life–Related Symptoms in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2015, 12, 370-375.	1.5	31
86	Genome-wide association study of subclinical interstitial lung disease in MESA. Respiratory Research, 2017, 18, 97.	1.4	31
87	The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia. Journal of Heart and Lung Transplantation, 2016, 35, 500-507.	0.3	30
88	Predictors of Length of Hospital Stay After Complete Repair for Tetralogy of Fallot: A Prospective Cohort Study. Journal of the American Heart Association, 2018, 7, .	1.6	30
89	Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis. European Respiratory Journal, 2019, 53, 1802237.	3.1	30
90	Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study. Thorax, 2017, 72, 472-474.	2.7	29

#	Article	IF	CITATIONS
91	The presence of Aspergillus fumigatus is associated with worse respiratory quality of life in cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 125-130.	0.3	28
92	Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. American Heart Journal, 2014, 167, 218-225.e1.	1.2	27
93	Noninvasive Ventilation Use Is Associated with Better Survival in Amyotrophic Lateral Sclerosis. Annals of the American Thoracic Society, 2021, 18, 486-494.	1.5	27
94	Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. Annals of the American Thoracic Society, 2021, 18, 613-622.	1.5	27
95	The Post–Pulmonary Embolism Syndrome: Real or Ruse?. Annals of the American Thoracic Society, 2019, 16, 811-814.	1.5	26
96	Sorafenib in Hepatopulmonary Syndrome: A Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. Liver Transplantation, 2019, 25, 1155-1164.	1.3	26
97	Association of right atrial structure with incident atrial fibrillation: a longitudinal cohort cardiovascular magnetic resonanceÂstudy from the Multi-Ethnic Study of AtherosclerosisÂ(MESA). Journal of Cardiovascular Magnetic Resonance, 2020, 22, 36.	1.6	26
98	Plasma serotonin levels are normal in pulmonary arterial hypertension. Pulmonary Pharmacology and Therapeutics, 2008, 21, 112-114.	1.1	25
99	Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2). Hepatology, 2021, 73, 726-737.	3.6	24
100	EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. European Respiratory Journal, 2021, 57, 2000414.	3.1	24
101	Particulate Matter Exposure and Cardiopulmonary Differences in the Multi-Ethnic Study of Atherosclerosis. Environmental Health Perspectives, 2016, 124, 1166-1173.	2.8	23
102	Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-8.	0.8	23
103	The Pulmonary Hypertension Association Registry: Rationale, Design, and Role in Quality Improvement. Advances in Pulmonary Hypertension, 2018, 16, 185-188.	0.1	23
104	Not All Measures of Hyperinflation Are Created Equal. Chest, 2014, 145, 1305-1315.	0.4	22
105	Noninvasive Tests for the Diagnostic Evaluation of Dyspnea Among Outpatients: The Multi-Ethnic Study of Atherosclerosis Lung Study. American Journal of Medicine, 2015, 128, 171-180.e5.	0.6	22
106	Classifying Patients with Amyotrophic Lateral Sclerosis by Changes in FVC. A Group-based Trajectory Analysis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1513-1521.	2.5	21
107	Right Ventricular Structure and Function Are Associated With Incident Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	20
108	Profiling the Role of Mammalian Target of Rapamycin in the Vascular Smooth Muscle Metabolome in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2015, 5, 667-680.	0.8	19

#	Article	IF	CITATIONS
109	Associations between emphysema-like lung on CT and incident airflow limitation: a general population-based cohort study. Thorax, 2018, 73, 486-488.	2.7	19
110	Genome-wide association analysis reveals insights into the genetic architecture of right ventricular structure and function. Nature Genetics, 2022, 54, 783-791.	9.4	19
111	Regional Left Ventricular Systolic Function and the Right Ventricle. Chest, 2011, 140, 310-316.	0.4	18
112	Effect of Single vs Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis. Chest, 2011, 140, 489-496.	0.4	18
113	H <sub>2</sub> Receptor Antagonists and Right Ventricular Morphology: The MESA Right Ventricle Study. Annals of the American Thoracic Society, 2014, 11, 1379-1386.	1.5	18
114	Erythropoietin Upregulation in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2014, 4, 269-279.	0.8	18
115	Ambient air pollution and pulmonary vascular volume on computed tomography: the MESA Air Pollution and Lung cohort studies. European Respiratory Journal, 2019, 53, 1802116.	3.1	18
116	Matrix metalloproteinase-9 and plasminogen activator inhibitor-1 are associated with right ventricular structure and function: The MESA-RV Study. Biomarkers, 2010, 15, 731-738.	0.9	17
117	Portopulmonary Hypertension: A Survey of Practice Patterns and Provider Attitudes. Transplantation Direct, 2019, 5, e456.	0.8	17
118	Associations of Serum Adipokines With Subclinical Interstitial Lung Disease Among Community-Dwelling Adults. Chest, 2020, 157, 580-589.	0.4	17
119	Advancing Clinical Trial Design in Pulmonary Hypertension. Pulmonary Circulation, 2013, 3, 217-225.	0.8	16
120	A prospective study of the 6â€min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naÃīve systemic sclerosis-associated pulmonary arterial hypertension. Annals of the Rheumatic Diseases, 2016, 75, 1457-1465.	0.5	16
121	Clinical Impact of Intrapulmonary Vascular Dilatation in Candidates for Liver Transplant. Chest, 2018, 153, 414-426.	0.4	16
122	Circulating adhesion molecules and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. European Respiratory Journal, 2019, 54, 1900295.	3.1	16
123	Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry. Journal of Heart and Lung Transplantation, 2020, 39, 945-953.	0.3	15
124	Intravenous Immunoglobulin for Hypogammaglobulinemia after Lung Transplantation: A Randomized Crossover Trial. PLoS ONE, 2014, 9, e103908.	1.1	14
125	Inhaled antibiotic use is associated with <i>Scedosporium/Lomentospora</i> species isolation in cystic fibrosis. Pediatric Pulmonology, 2019, 54, 133-140.	1.0	14
126	Impact of Maternal–Fetal Environment on Mortality in Children With Single Ventricle Heart Disease. Journal of the American Heart Association, 2022, 11, e020299.	1.6	14

#	Article	IF	CITATIONS
127	Association of Systemic Arterial Properties With Right Ventricular Morphology: The Multiâ€Ethnic Study of Atherosclerosis (MESA)â€Right Ventricle Study. Journal of the American Heart Association, 2016, 5, .	1.6	13
128	Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the) Tj ETQq0 0 0 rgBT	Overlock 2 0.7	10 Tf 50 707 1 13
129	Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. Annals of the American Thoracic Society, 2022, 19, 1459-1468.	1.5	13
130	Adverse Events in Connective Tissue Disease–Associated Pulmonary Arterial Hypertension. Arthritis and Rheumatology, 2015, 67, 2457-2465.	2.9	12
131	Endothelin-1, cardiac morphology, and heart failure: the MESA angiogenesis study. Journal of Heart and Lung Transplantation, 2020, 39, 45-52.	0.3	12
132	Associations of Angiopoietins With Heart Failure Incidence and Severity. Journal of Cardiac Failure, 2021, 27, 786-795.	0.7	12
133	Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis. European Respiratory Journal, 2022, 60, 2102304.	3.1	12
134	Secular and Regional Trends among Pulmonary Arterial Hypertension Clinical Trial Participants. Annals of the American Thoracic Society, 2022, 19, 952-961.	1.5	12
135	Brachial Artery Diameter and the Right Ventricle. Chest, 2012, 142, 1399-1405.	0.4	11
136	Pentraxinâ€3 and the Right Ventricle: The Multiâ€Ethnic Study of Atherosclerosis–Right Ventricle Study. Pulmonary Circulation, 2014, 4, 250-259.	0.8	11
137	Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research. European Respiratory Journal, 2017, 50, 1700983.	3.1	11
138	Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of Atherosclerosis. Respiratory Medicine, 2018, 140, 108-114.	1.3	11
139	Right ventricular outflow tract velocity time integral-to-pulmonary artery systolic pressure ratio: a non-invasive metric of pulmonary arterial compliance differs across the spectrum of pulmonary hypertension. Pulmonary Circulation, 2019, 9, 204589401984197.	0.8	11
140	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circulation: Heart Failure, 2021, 14, .	1.6	11
141	Selective Serotonin Reuptake Inhibitor Use Is Associated with Right Ventricular Structure and Function: The MESA-Right Ventricle Study. PLoS ONE, 2012, 7, e30480.	1.1	11
142	Associations of Monocyte Count and Other Immune Cell Types with Interstitial Lung Abnormalities. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 795-805.	2.5	11
143	Percent Emphysema and Daily Motor Activity Levels in the General Population. Chest, 2017, 151, 1039-1050.	0.4	10
144	Pulmonary hyperinflation due to gas trapping and pulmonary artery size: The MESA COPD Study. PLoS ONE, 2017, 12, e0176812.	1.1	10

#	Article	IF	CITATIONS
145	Longitudinal Associations of Fitness and Obesity in Young Adulthood With Right Ventricular Function and Pulmonary Artery Systolic Pressure in Middle Age: The CARDIA Study. Journal of the American Heart Association, 2021, 10, e016968.	1.6	10
146	Regional distribution of high-attenuation areas on chest computed tomography in the Multi-Ethnic Study of Atherosclerosis. ERJ Open Research, 2020, 6, 00115-2019.	1.1	9
147	Loss of Pulmonary Vascular Volume as a Predictor of Right Ventricular Dysfunction and Mortality in Acute Pulmonary Embolism. Circulation: Cardiovascular Imaging, 2021, 14, e012347.	1.3	9
148	Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT. Contemporary Clinical Trials, 2011, 32, 280-287.	0.8	8
149	Slow-paced respiration therapy to treat symptoms in pulmonary arterial hypertension. Heart and Lung: Journal of Acute and Critical Care, 2017, 46, 7-13.	0.8	8
150	Pulmonary artery stiffness in chronic obstructive pulmonary disease (COPD) and emphysema: The Multi‣thnic Study of Atherosclerosis (MESA) COPD Study. Journal of Magnetic Resonance Imaging, 2018, 47, 262-271.	1.9	8
151	Right Ventricular Morphology and the Onset of Dyspnea: The MESA-Right Ventricle Study. PLoS ONE, 2013, 8, e56826.	1.1	8
152	Pericardial Fat and Right Ventricular Morphology: The Multi-Ethnic Study of Atherosclerosis- Right Ventricle Study (MESA-RV). PLoS ONE, 2016, 11, e0157654.	1.1	8
153	Remote 6-Minute-Walk Testing in Patients with Pulmonary Hypertension: A Pilot Study. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 851-854.	2.5	8
154	Update in Pulmonary Vascular Diseases 2014. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 544-550.	2.5	7
155	Sex Differences in Portopulmonary Hypertension. Chest, 2021, 159, 328-336.	0.4	7
156	Risk of primary graft dysfunction following lung transplantation in selected adults with connective tissue disease-associated interstitial lung disease. Journal of Heart and Lung Transplantation, 2021, 40, 351-358.	0.3	7
157	Identifying Risk Factors for Complicated Post-operative Course in Tetralogy of Fallot Using a Machine Learning Approach. Frontiers in Cardiovascular Medicine, 2021, 8, 685855.	1.1	7
158	Adipokines and the Right Ventricle: The MESA-RV Study. PLoS ONE, 2015, 10, e0136818.	1.1	6
159	Ambient Coarse Particulate Matter and the Right Ventricle: The Multi-Ethnic Study of Atherosclerosis. Environmental Health Perspectives, 2017, 125, 077019.	2.8	6
160	Association of long pentraxin-3 with pulmonary hypertension and primary graft dysfunction in lung transplant recipients. Journal of Heart and Lung Transplantation, 2018, 37, 792-794.	0.3	6
161	Preoperative echocardiographic parameters predict primary graft dysfunction following pediatric lung transplantation. Pediatric Transplantation, 2021, 25, e13858.	0.5	6
162	Physical Activity and Its Association with Traditional Outcome Measures in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2022, 19, 572-582.	1.5	6

#	Article	IF	CITATIONS
163	BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension. Chest, 2022, 162, 436-447.	0.4	6
164	Von Willebrand Factor and the Right Ventricle (the MESA-Right Ventricle Study). American Journal of Cardiology, 2012, 110, 1846-1851.	0.7	5
165	Determinants of 6â€Minute Walk Distance in Patients with Idiopathic Pulmonary Fibrosis Undergoing Lung Transplant Evaluation. Pulmonary Circulation, 2016, 6, 30-36.	0.8	5
166	Antacid use and subclinical interstitial lung disease: the MESA study. European Respiratory Journal, 2017, 49, 1602566.	3.1	5
167	Prevalence and Impact of Restrictive Lung Disease in Liver Transplant Candidates. Liver Transplantation, 2020, 26, 989-999.	1.3	5
168	Connective tissue disease-associated pulmonary arterial hypertension: "Beijing style― European Respiratory Journal, 2014, 44, 839-841.	3.1	4
169	A Semi-Automated Term Harmonization Pipeline Applied to Pulmonary Arterial Hypertension Clinical Trials. Methods of Information in Medicine, 2022, 61, 003-010.	0.7	4
170	What's the (end) point?. European Respiratory Journal, 2015, 45, 853-854.	3.1	3
171	Risk factors for 30â€day readmission in adults hospitalized for pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-14.	0.8	3
172	Relax or Contract. Circulation, 2013, 128, 1999-2001.	1.6	2
173	What is new about Rio?. European Respiratory Journal, 2015, 45, 1211-1213.	3.1	2
174	SIX-MINUTE WALK DISTANCE AND B-TYPE NATRIURETIC PEPTIDE AS DISCRIMINATORS OF SURVIVAL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Chest, 2009, 136, 22S.	0.4	1
175	Magnetic Resonance Imaging in Pulmonary Arterial Hypertension. Panacea or Pixelation?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 129-131.	2.5	1
176	Antinuclear antibodies and subclinical interstitial lung disease in community-dwelling adults: the MESA study. European Respiratory Journal, 2020, 55, 1902262.	3.1	1
177	Prescription Patterns for Pulmonary Vasodilators in the Treatment of Pulmonary Hypertension Associated With Chronic Lung Diseases: Insights From a Clinician Survey. Frontiers in Medicine, 2021, 8, 764815.	1.2	1
178	A Survey of Implementation of ABCDE Protocols. Journal of Intensive Care Medicine, 2023, 38, 86-94.	1.3	1
179	Reply. Journal of the American College of Cardiology, 2014, 64, 739.	1.2	0
180	BMPR2 revisited: are bigger data better?. Lancet Respiratory Medicine,the, 2016, 4, 87-89.	5.2	0

#	Article	IF	CITATIONS
181	Predicting respiratory failure in amyotrophic lateral sclerosis: still a long way to go. European Respiratory Journal, 2019, 54, 1901221.	3.1	0
182	Response. Chest, 2019, 156, 187-188.	0.4	0
183	Insulin Resistance Is Associated with Right Ventricular Dysfunction. Annals of the American Thoracic Society, 2022, 19, 562-571.	1.5	0
184	Association between antinuclear antibody seropositivity and telomere length: a nationwide population-based study. Clinical and Experimental Rheumatology, 2020, 38, 989-992.	0.4	0
185	Reply to: Remote 6-minute Walk Testing in Patients with Pulmonary Hypertension: Further Validation Needed?. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	Ο